The era of compound management for obesity
By Whang, byung-woo | translator Alice Kang
25.01.23 05:40:11
가나다라
0
Need to treat obesity, lose weight, and manage comorbidities such as hypertension at the same time to manage obesity
Clinical benefits such as weight loss, and cardiovascular risk reduction are expected with Wegovy
Prescription limitations exist due to non-reimbursement...Novo Nordisk “looks for ways to expand access”
Wegovy (semaglutide), an obesity drug hailed as a game-changer, is seeking synergy with its cardiovascular benefits in addition to weight loss.
Experts say that the obesity treatment paradigm is already evolving beyond weight loss to overall health care. In the future, it will be a challenge to improve access through expert review and reimbursement.
▲(from the left) Soo Lim, Professor of endocrinology and metabolism at Seoul National University Bundang Hospital, Jong Chan Yoon, Professor of Cardiology at Seoul St. Mary
Novo Nordisk held a media session on the 21st of this month to highlight the weight loss and cardiovascular disease risk reduction effects of Wegovy.
Wegovy is an obesity treatment that is administered once a week. It is licensed in Korea as an adjunct to weight loss and weight management in patients with weight-related
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)